TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24635773

Group type: EXPERIMENTAL
Intervention: Protocol-based early goal-directed therapy (EGDT)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Protocol-based standard therapy
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Protocol-based EGDT vs. usual care
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Protocol-based EGDT vs. protocol-based standard therapy
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1341
Study: 23082174

Group type: EXPERIMENTAL
Intervention: Active tDCS at 2 mA for 20 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham tDCS at 2 mA for 20 minutes
Number of subjects: 100
Study: 20947305

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20mg p.o)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: random/matched alternate version of the GMLT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 16998094

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (300 mg/d)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 16266416

Group type: EXPERIMENTAL
Intervention: Leaflet intervention for older patients to prepare for consultations and outreach visit to GPs.
Number of subjects: 263

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 263
Study: 12151034

Group type: EXPERIMENTAL
Intervention: CCK-8S 10 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCK-8S 20 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10453446

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 8519046

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3476241

Group type: EXPERIMENTAL
Intervention: Extensive Amalgam Restorations (EAR)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Operator influence
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Retention methods
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Side location of the tooth
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Extension of the restoration
Number of subjects: 269
Study: 30483710

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M3
Number of subjects: 45
Study: 26944539

Group type: COMPARATOR
Intervention: 2-g progesterone intravaginal device on Day -23
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: 400 IU of equine chorionic gonadotropin (eCG)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Extended progesterone treatment combined with eCG
Number of subjects: 570
Study: 23768612

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 30 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Casein Protein (CP) 30 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) 33 g
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 22439807

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (TU) four times/year for 36 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (age-matched hypogonadal men with MS)
Number of subjects: 60
Study: 21084720

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 0
Study: 18019739

Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 18
Study: 16268972

Group type: EXPERIMENTAL
Intervention: Meal intake
Number of subjects: 12
Study: 12383665

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (more than 3.5 applicators per working day)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (less than 3.5 applicators per working day)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892
Study: 10094160

Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upright faces
Number of subjects: 0
Study: 8920704

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb high-titre vaccine (EZ-HT,5m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schwarz standard measles vaccine (SW-STD,10m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schwarz high-titre vaccine (SW-HT,5m)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-titre vaccines (EZ-HT and SW-HT)
Number of subjects: 0
Study: 2012902

Group type: EXPERIMENTAL
Intervention: Same hearing aid system on two occasions
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Two acoustically different aids on two occasions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of two NHS hearing aid systems
Number of subjects: 56
Study: 6807524

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 155
Study: 31106381

Group type: EXPERIMENTAL
Intervention: Rapidly Cycling Work Roster (RCWR)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Extended Duration Work Roster (EDWR)
Number of subjects: 302
Study: 28693531

Group type: EXPERIMENTAL
Intervention: Warm-needling acupuncture and medicinal cake-separated moxibustion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 130
Study: 25393983

Group type: EXPERIMENTAL
Intervention: Microsurgical group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Macrosurgical group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study: 23404832

Group type: EXPERIMENTAL
Intervention: LIFESTYLE
Number of subjects: 240

Group type: COMPARATOR
Intervention: USUAL CARE
Number of subjects: 240
Study: 21992490

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) injection 0.015%
Number of subjects: 91

Group type: COMPARATOR
Intervention: Limbal conjunctival autograft transplantation (LCAT)
Number of subjects: 91
Study: 19517895

Group type: EXPERIMENTAL
Intervention: 4 mg Dexmethsone tablets (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4 mg tablets of the originator product (reference formulation)
Number of subjects: 24
Study: 17604592

Group type: EXPERIMENTAL
Intervention: Gabapentin adjuvant to ongoing opioid treatment (group GO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Opioid monotherapy (group OO)
Number of subjects: 75
Study: 15555792

Group type: EXPERIMENTAL
Intervention: Thermodilution (TDD) group treated according to volumetric preload endpoint (intrathoracic blood volume) obtained by invasive haemodynamic monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group resuscitated according to the Baxter formula (4 ml/kg BW/% BSA burn)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 50
Study: 11173893

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation with standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.) for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation with standard triple therapy
Number of subjects: 120
Study: 9493716

Group type: EXPERIMENTAL
Intervention: Melatonin administration (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light exposure
Number of subjects: 0
Study: 9272896

Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy and the first 2 years of the child's life
Number of subjects: 1139
Study: 2241050

Group type: EXPERIMENTAL
Intervention: Intra-articular and subcutaneous prilocaine with adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27947

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30801621

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (AP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Anticoagulation therapy (AC)
Number of subjects: 250
Study: 28069663

Group type: EXPERIMENTAL
Intervention: Aerobic cybercycling PE curriculum (7-week intervention, 2 times per week, 30-40 minutes per session)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard nonaerobic PE (control period)
Number of subjects: 103
Study: 26045340

Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine and cisplatin
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin
Number of subjects: 1093
Study: 22188329

Group type: EXPERIMENTAL
Intervention: Cold atmospheric argon plasma for 2 min daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Argon gas (placebo)
Number of subjects: 46
Study: 21536968

Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: No SHS exposure (Control)
Number of subjects: 24
Study: 19507407

Group type: EXPERIMENTAL
Intervention: Vitamin C with metabolites (Ester-C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study: 17535146

Group type: EXPERIMENTAL
Intervention: Usual care plus an individually tailored exercise program administered twice daily from hospital admission to discharge
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 236
Study: 15519089

Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Amvisc Plus (sodium hyaluronate 1.6%)
Number of subjects: 140
Study: 11509774

Group type: EXPERIMENTAL
Intervention: Hydro ThermAblator (HTA)
Number of subjects: 276

Group type: COMPARATOR
Intervention: rollerball
Number of subjects: 276
Study: 9739992

Group type: COMPARATOR
Intervention: No fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 0
Study: 8072075

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 micrograms prostaglandin E1 with 10 mg procaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 micrograms prostaglandin E1 with 20 mg procaine
Number of subjects: 24
Study: 3062268

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31383448

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Seed acupressure
Number of subjects: 31
Study: 28454831

Group type: EXPERIMENTAL
Intervention: Medisafe mhealth application
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study: 25256813

Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy every 6 months (3 weekly instillations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy every 3 months (2 weekly instillations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy
Number of subjects: 0
Study: 23253774

Group type: EXPERIMENTAL
Intervention: Peri-interventional antibiotic prophylaxis (1.2 g amoxicillin/clavulanic acid during stent insertion)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Continuous low-dose antibiotic treatment (625 mg amoxicillin/clavulanic acid once daily until stent removal)
Number of subjects: 95
Study: 21296338

Group type: EXPERIMENTAL
Intervention: Prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 19583075

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (ISO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketamine‐midazolam‐fentanyl total intravenous anesthesia (TIVA)
Number of subjects: 15
Study: 16732095

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.05-0.6 mg/70 kg
Number of subjects: 0
Study: 15307696

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus 15 ml of milkvetch injection (MI) every 12 hrs for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 40
Study: 10835440

Group type: EXPERIMENTAL
Intervention: 1 mg/h nimodipine (low-dose)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 2 mg/h nimodipine (high-dose)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 9132212

Group type: EXPERIMENTAL
Intervention: 18 week walking programme (900 kcal week‐1 for total duration, 1161 kcal week‐1 during final six weeks, intensity of 67.8% of maximum oxygen consumption)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 8262843

Group type: COMPARATOR
Intervention: Standard radiotherapy (70 Gy/35 fractions/7 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Concomitant boost technique (75 Gy/40 fractions/6 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nodal status
Number of subjects: 42
Study: 4087694

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 14
Study: 29415593

Group type: EXPERIMENTAL
Intervention: ≥1 serving of fish per week
Number of subjects: 852

Group type: COMPARATOR
Intervention: <1 serving of fish per week
Number of subjects: 852
Study: 29133080

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 933
Study: 26911633

Group type: EXPERIMENTAL
Intervention: mexiletine 300 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mexiletine 900 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 25185672

Group type: EXPERIMENTAL
Intervention: Alogliptin with lansoprazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alogliptin mono-therapy
Number of subjects: 100
Study: 22268920

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 60 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21034177

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Travoprost 0.004% once daily
Number of subjects: 72
Study: 17951479

Group type: EXPERIMENTAL
Intervention: Prebiotic-supplemented hypoallergenic formula (8 g/L scGOS/lcFOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-supplemented hypoallergenic formula (8 g/L maltodextrin)
Number of subjects: 0
Study: 15876285

Group type: EXPERIMENTAL
Intervention: Once-daily therapy with stavudine prolonged-release capsule (PRC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Twice-daily regimens based on stavudine immediate release or zidovudine
Number of subjects: 43
Study: 12530019

Group type: EXPERIMENTAL
Intervention: Cisplatinum/Treosulfan (PT)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Cisplatinum/Cyclophosphamide (PC)
Number of subjects: 519
Study: 9800147

Group type: EXPERIMENTAL
Intervention: Lamotrigine 250 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lamotrigine 500 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7634805

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg i.v. over 30 mins)
Number of subjects: 10
Study: 2501516

Group type: EXPERIMENTAL
Intervention: Cystoscopy performed 3 months after initial transurethral resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of tumors at presentation (single or multiple)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up procedures based on prognosis groups
Number of subjects: 0
Study: 325598

Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine (2% and 1%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study: 31354106

Group type: EXPERIMENTAL
Intervention: Relaxed α-levels (up to 0.1) in series of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analysis with futility rule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analysis for efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-arm trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-arm trials
Number of subjects: 0
Study: 30919151

Group type: EXPERIMENTAL
Intervention: Single 500‐mg tablet of levofloxacin without enema (Group A)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Single 500‐mg tablet of levofloxacin plus enema (Group B)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 3‐day levofloxacin orally plus enema (Group C)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Group A (500 mg levofloxacin without enema)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Group B (500 mg levofloxacin plus enema)
Number of subjects: 420
Study: 29282143

Group type: EXPERIMENTAL
Intervention: Azithromycin (12-month course, weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26703278

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.4% (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1% (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No NSAIDs (Group D, control)
Number of subjects: 120
Study: 23909049

Group type: EXPERIMENTAL
Intervention: Atopy patch tests with aeroallergens (1 x skin prick tests concentration)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Specific IgE and skin prick tests
Number of subjects: 29
Study: 21764428

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 8122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8122
Study: 18843180

Group type: EXPERIMENTAL
Intervention: Active laser therapy 20 min a day for 3 months with a 650‐nm, 5‐mW soft laser (group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dummy device (group C)
Number of subjects: 60
Study: 16959660

Group type: EXPERIMENTAL
Intervention: ArginMax for women
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 15340661

Group type: EXPERIMENTAL
Intervention: Etanercept plus Methotrexate (MTX)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 58
Study: 10932510

Group type: EXPERIMENTAL
Intervention: Stone-former group (external oblique muscle)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group I (external oblique muscle)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group II (rectus abdominis muscle)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group III (quadriceps femoris muscle)
Number of subjects: 202
Study: 9008503

Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 8388307

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3802699

Group type: EXPERIMENTAL
Intervention: Activated charcoal plus 75 ml 70% sorbitol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Activated charcoal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 30755472

Group type: EXPERIMENTAL
Intervention: NAVA through a helmet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure support through a face mask
Number of subjects: 10
Study: 29217375

Group type: EXPERIMENTAL
Intervention: 5 μg ZPIV vaccine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 67
Study: 27018060

Group type: EXPERIMENTAL
Intervention: Individually tailored 12-week home-based exercise programme of treadmill interval training and strength exercises
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting Control Group (usual care)
Number of subjects: 26
Study: 24797657

Group type: EXPERIMENTAL
Intervention: IQP-GC-101
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 22702906

Group type: EXPERIMENTAL
Intervention: Elacytarabine 2000 mg/m² per day continuously i.v. during days 1‐5 every 3 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 61
Study: 20036549

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 148
Study: 17662114

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 720

Group type: COMPARATOR
Intervention: Expectant management for spontaneous delivery
Number of subjects: 720
Study: 15330404

Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 18
Study: 11220425

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam administered 30 min preoperatively
Number of subjects: 73

Group type: COMPARATOR
Intervention: 20 mg tenoxicam administered at induction of anesthesia
Number of subjects: 73
Study: 9426331

Group type: EXPERIMENTAL
Intervention: Filgrastim initiated on day 4
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Filgrastim initiated on day 6
Number of subjects: 46

Group type: COMPARATOR
Intervention: Filgrastim initiated on day 8
Number of subjects: 46
Study: 8032065

Group type: EXPERIMENTAL
Intervention: Sustanon 250 (250 mg, 1 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 30
Study: 2891992

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 29751823

Group type: EXPERIMENTAL
Intervention: KENKOJISEICHI group - 90-minute sessions twice per week for 6 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Educational control group - 120-minute educational classes during the 6-month trial period
Number of subjects: 83